<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02808611</url>
  </required_header>
  <id_info>
    <org_study_id>N-20150055</org_study_id>
    <nct_id>NCT02808611</nct_id>
  </id_info>
  <brief_title>Influence of Propranolol on Conditioned Pain Modulation</brief_title>
  <official_title>Konditionerende Smertestimuli - Sammenligning af Forskellige Test og Konditioneringsmodaliteter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kristian Kjær Petersen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aalborg University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An extensive amount of studies indicate that conditioned pain modulation (CPM) test paradigms
      can be of use to evaluate the efficacy of the endogenous pain inhibition pathway in healthy
      controls and pain patients. A number of studies indicate that the autonomic nervous system
      (ANS) responds to painful stimulation by parasympathetic activity withdrawal and
      up-regulation of sympathetic activity (flight-or-fight mode), but it remains unknown whether
      these responses predict individual pain susceptibility or CPM efficacy and whether different
      pain modalities evoke different physiological stress responses, i.e. do individuals with low
      pain tolerance exhibit more vigorous ANS responses when subjected to controlled acute pain
      stimuli, and do high ANS responsiveness to pain coincide with altered psychophysical pain
      levels/CPM efficacy.

      This study aims to investigate the effect of ANS responsiveness on CPM paradigms and to
      investigate if an exogenous, pharmaceutically induced decrease in the sympathetic drive of
      the ANS will yield decreased CPM efficacy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Actual">January 2017</completion_date>
  <primary_completion_date type="Actual">January 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CPM efficacy</measure>
    <time_frame>1-2 hours after propranolol/placebo and after 10 minutes break.</time_frame>
    <description>A test stimuli will be applied and compared with a test stimuli simultaneous a condition stimuli.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Temporal summation of pain</measure>
    <time_frame>1-2 hours after propranolol/placebo and after 10 minutes break.</time_frame>
    <description>10 stimuli will be applied and subjects will back asked to rate the pain for each individual stimuli.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart-rate variability</measure>
    <time_frame>1-2 hours after propranolol/placebo and after 10 minutes break.</time_frame>
    <description>Two-point Heart-rate variability recording will be conducted using the Polar RS800CX heart rate monitor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Offset analgesia</measure>
    <time_frame>1-2 hours after propranolol/placebo and after 10 minutes break.</time_frame>
    <description>Temperatures ranging from 45-48°C will be applied to the forearm in three phases (phase 1: 5 seconds, phase 2: 5 seconds, and phase 3: 20 seconds). The subjects will be asked to assess the pain of the thermal stimuli using the electronic VAS scale.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Propranolol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Propranolol is a beta-blocker</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propranolol</intervention_name>
    <description>Reduction of the ANS response</description>
    <arm_group_label>Propranolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects

        Exclusion Criteria:

          -  Drug addiction defined as the use of cannabis, opioids or other drugs

          -  Previous history of neurologic, musculoskeletal, mental illnesses or a chronic pain
             condition

          -  Lack of ability to cooperate

          -  Current use of medications that may affect the trial, e.g., analgesics,
             anti-inflammatory drugs

          -  Consumption of alcohol, caffeine, nicotine or painkillers the morning and until
             termination of the study on the study day

          -  Recent history of acute pain affecting the lower limb

          -  Participation in other pain trials throughout the study period

          -  Known diagnosis of cardio vascular diseases (low blood pressure, heart conditions)

          -  Asthma

          -  Decreased function of liver and kidneys

          -  Diabetes
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>KRISTIAN K PETERSEN, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aalborg University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Sensory Motor Interaction, Aalborg University</name>
      <address>
        <city>Aalborg East</city>
        <zip>9220</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2016</study_first_submitted>
  <study_first_submitted_qc>June 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2016</study_first_posted>
  <last_update_submitted>June 27, 2017</last_update_submitted>
  <last_update_submitted_qc>June 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Aalborg University</investigator_affiliation>
    <investigator_full_name>Kristian Kjær Petersen</investigator_full_name>
    <investigator_title>M.Sc, Ph.d.</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

